adMare
News

News - Thumbnail

February 27 2024

Domain Therapeutics promotes Stephan Schann as Chief Scientific Officer (CSO)

Read
News - Thumbnail

November 08 2023

Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions

Read
News - Thumbnail

October 10 2023

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Read
News - Thumbnail

September 25 2023

Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial

– ZONE study to evaluate the effect of ZT-01 on preventing nighttime hypoglycemia in people with Type 1 diabetes –

– ZT-01 has the potential to become the first therapeutic to prevent nocturnal hypoglycemia, a condition for which there are currently no available therapies –

Read
News - Thumbnail

August 25 2023

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study.

Read
News - Thumbnail

August 15 2023

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

 

Read
News - Thumbnail

August 10 2023

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

 

Read
News - Thumbnail

July 24 2023

Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.

Read
News - Thumbnail

July 05 2023

Abdera’s Success: adMare model of company creation 

 

Read
News - Thumbnail

June 29 2023

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies

 

Read
News - Thumbnail

June 15 2023

Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023 

 

Read
News - Thumbnail

June 08 2023

Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec

 

Read